ArticleJournal of biomedical physics & engineering2025
An in Vitro Study on Anticancer Efficacy of Capecitabine- and Vorinostat-incorporated Self-nanoemulsions.
Article in Journal of biomedical physics & engineering, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cancer has emerged as a critical global health concern due to its widespread prevalence and impact on individuals, families, communities, and healthcare systems worldwide. Objective: We investigated the anticancer effectiveness of capecitabine (CAP) and vorinostat (VOR) when incorporated into self-nanoemulsifying drug delivery systems (SNEDDSs). Material and Methods: In this experimental study, the SNEDDSs were formulated using polyethylene glycol 600 (PEG 600), castor oil and Tween 80. A ternary phase diagram was plotted for the SNEDDSs components and the single-phase formation region was attained. SNEDDSs were then prepared by dilution of the selected ratios of these components in water. Blank SNEDDSs containing ratios (in weight) of castor oil:Tween 80:PEG 600 of 50:30:20 (S1-SNEDDS) and 25:15:60 (S2-SNEDDS) were selected. S1-SNEDDS was loaded with CAP (S1-SNEDDS-CAP), and S2-SNEDDS was loaded with VOR (S2-SNEDDS-VOR). Results: The developed SNEDDSs formed oil nanodroplets without phase separation. Using dynamic laser light scattering, S1-SNEDDS, S2-SNEDDS, S1-SNEDDS-CAP and S2-SNEDDS-VOR had droplets with average sizes of 171±37, 82±18, 117±26 and 37±8 nm, respectively, accompanied by span values of 0.96, 0.95, 0.97 and 0.96, respectively. CAP and VOR were effectively loaded into the SNEDDSs with high entrapment efficiencies and loading capacities. Considerable improvements in cells viability for CAP and VOR were attained upon loading into SNEDDSs. TUNEL assays of the cells upon treatment by S1-SNEDDS-CAP and S2-SNEDDS-VOR revealed a significant apoptosis in all the cells. Conclusion: The study provides valuable insights into the potential of utilizing SNEDDSs as a novel delivery system for improving the anticancer properties of CAP and VOR.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.